| Main Subject |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Management > Innovation Management - some ideas are better than others |
|
Main Subject - Innovation Management - some ideas are better than others
Creativity can be defined as problem identification and idea generation whilst innovation can be defined as idea sel According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ection, development and commercialisation. There are distinct processes that enhance problem identification and ide ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in a generation and, similarly, distinct processes that enhance idea selection, development and commercialisation. Whil lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. st there is no sure fire route to commercial success, these processes improve the probability that good ideas will b here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe generated and selected and that investment in developing and commercialising those ideas will not be wasted. One o d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro f the useful methods of valuing ideas is to compare the type of idea with those types of ideas that have previously ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc been most successful. Franklin (2003) notes that some kinds of ideas are more successful than others. He notes six easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi ypes: a) Need spotting – involves actively finding an answer to a problem. b) Solution spotting – involves finding nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically a problem for a solution. c) Market Research – ideas generated as a result of market research. d) Random event – and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ moments of serendipity when people stumble across answers they weren’t looking for. e) Mental invention – pure rand ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi m ideas with no previous knowledge of how they may be implemented. f) Trend following. Of these, the random event ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a was the most successful (92.9%) with least failures (7.1%). However, this type of idea requires previous knowledge o dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod r experience on some level – for example, an individual who has worked in an environment previously may utilise that cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin tacit knowledge to solve a problem that becomes evident later. Very close to the above is solution spotting with a tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen 87.5% success and a 12.5% failure rate. Again, this idea type requires previous knowledge: the innovator consciousl t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel y seeks a problem to apply that knowledge to. These topics are covered in depth in the MBA dissertation on Managing ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust Creativity & Innovation, which can be purchased (along with a Creativity and Innovation DIY Audit, Good Idea Genera y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products or Software and Power Point Presentation) from http://www.managing-creativity.com. You can also receive a regular, . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de free newsletter by entering your email address at this site. Kal Bishop, MBA ********************************** Y elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip ou are free to reproduce this article as long as no changes are made and the author's name and site URL are retained tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Advertising Inside Video Games - A Good Corporate Move Indeed Corporate Branding: A High Priority For All Companies
|